Skip to main content
    A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.31
    -0.05 (-0.60%)

    Market Cap: $240.96M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcturus Therapeutics Holdings Inc (ARCT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Arcturus Therapeutics Holdings (ARCT) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Arcturus Therapeutics Holdings reported EPS of -$0.26, above the -$0.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +4.32%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.92
    Range-$1.52 - -$0.55
    15 analysts
    Revenue Consensus
    $5.22M
    Range$1.42M - $20.72M
    15 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.88
    Range-$1.05 - -$0.76
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.96+8.3%
    60d ago-$0.83-6.4%
    30d ago-$0.83-6.4%
    7d ago-$0.83-6.4%
    Current-$0.88
    Revenue Consensus
    $1.95M
    Range$600.00K - $3.83M
    5 analysts

    Next Report

    ARCT has an expected report date of Mar 1, 2027.

    ARCT Earnings Call

    The latest ARCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ARCT beat 23, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $18.30M, up 6.7% from $17.15M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.26-$0.60-$0.92 - -$0.29+56.67%BeatN/A100 up, 1 downNov 5, 2026$18.30M
    Jun 30, 2026-$0.84-$1.07-$1.35 - -$0.87+21.50%BeatN/A117 up, 3 downAug 6, 2026$2.96M
    Mar 31, 2026-$0.95-$1.01-$1.38 - -$0.07+6.25%BeatN/A111 up, 0 downMay 7, 2026$2.06M
    Dec 31, 2025-$1.03-$0.76-$1.27 - -$0.13-35.53%MissN/A10N/AMar 3, 2026$7.20M
    Sep 30, 2025-$0.49-$0.80-$1.66 - -$0.07+38.75%BeatN/A98 up, 0 downNov 10, 2025$17.15M
    Jun 30, 2025-$0.34-$0.85-$1.76 - -$0.34+60.00%BeatN/A94 up, 1 downAug 11, 2025$28.30M
    Mar 31, 2025-$0.52-$1.10-$2.10 - $0.19+52.73%BeatN/A80 up, 3 downMay 12, 2025$29.38M
    Dec 31, 2024-$1.11-$0.49-$1.24 - $0.59-124.56%MissN/A91 up, 0 downMar 6, 2025$22.77M
    Sep 30, 2024-$0.26-$1.02-$1.85 - -$0.15+74.51%BeatN/A110 up, 0 downNov 7, 2024$41.67M
    Jun 30, 2024-$0.64-$1.57-$2.11 - -$1.02+59.24%BeatN/A70 up, 0 downAug 5, 2024$49.86M
    Mar 31, 2024-$1.00-$1.14-$1.71 - -$0.84+12.28%Beat-258.7%80 up, 0 downMay 8, 2024$38.01M
    Dec 31, 2023-$0.32-$0.99-$2.18 - $1.84+67.68%Beat-107.2%100 up, 0 downMar 7, 2024$30.86M
    Sep 30, 2023-$0.61-$1.63-$2.67 - -$0.59+62.58%BeatN/A90 up, 0 downNov 14, 2023$45.14M
    Jun 30, 2023-$1.98-$0.42-$1.43 - $1.88-371.43%MissN/A80 up, 0 downAug 7, 2023$10.52M
    Mar 31, 2023$0.63$0.26-$2.07 - $2.92+142.31%BeatN/A80 up, 0 downMay 9, 2023$80.28M
    Dec 31, 2022$4.43$0.98-$2.38 - $5.86+352.04%BeatN/A110 up, 0 downMar 28, 2023$160.29M
    Sep 30, 2022-$1.33-$1.81-$2.41 - -$1.12+26.52%BeatN/A100 up, 1 downNov 9, 2022$13.37M
    Jun 30, 2022-$0.82-$1.88-$2.42 - -$1.24+56.38%BeatN/A110 up, 0 downAug 9, 2022$27.09M
    Mar 31, 2022-$1.94-$1.40-$2.43 - -$0.40-38.57%MissN/A110 up, 0 downMay 9, 2022$5.24M
    Dec 31, 2021-$1.47-$1.72-$2.22 - -$0.64+14.53%BeatN/A11N/AFeb 28, 2022$5.79M
    Sep 30, 2021-$2.05-$1.52-$2.59 - $0.29-34.87%MissN/A12N/ANov 8, 2021$2.44M
    Jun 30, 2021-$2.07-$2.25-$2.48 - -$1.22+8.00%BeatN/A14N/AAug 9, 2021$2.00M
    Mar 31, 2021-$2.15-$1.23-$1.68 - -$0.92-74.80%MissN/A13N/AMay 10, 2021$2.13M
    Dec 31, 2020-$1.25-$0.88-$1.26 - -$0.38-42.05%MissN/A13N/AMar 1, 2021$2.24M
    Sep 30, 2020-$0.92-$0.49-$0.63 - -$0.40-87.76%MissN/A12N/ANov 9, 2020$2.33M
    Jun 30, 2020-$0.55-$0.55-$0.72 - -$0.330.00%In lineN/A9N/AAug 10, 2020$2.32M
    Mar 31, 2020-$0.67-$0.61-$0.82 - -$0.30-9.84%MissN/A7N/AMay 7, 2020$2.65M
    Dec 31, 2019-$0.76-$0.51N/A-49.02%MissN/AN/AN/AMar 11, 2020$2.97M
    Sep 30, 2019-$0.56-$0.46N/A-21.74%MissN/AN/AN/ANov 7, 2019$3.32M
    Jun 30, 2019-$0.07-$0.61N/A+88.52%BeatN/AN/AN/AAug 15, 2019$10.15M
    Mar 31, 2019-$0.68-$0.60-$0.68 - -$0.51-13.33%MissN/A4N/AMay 13, 2019$4.35M
    Dec 31, 2018-$0.08-$0.48-$0.56 - -$0.42+83.33%BeatN/A4N/AMar 18, 2019$7.58M
    Sep 30, 2018-$0.42-$0.35N/A-20.00%MissN/AN/AN/AOct 1, 2018$3.42M
    Jun 30, 2018-$0.99-$0.70-$0.70 - -$0.70-41.43%MissN/A1N/ASep 28, 2018$2.39M
    Mar 31, 2018-$1.08-$0.46N/A-134.78%MissN/A1N/AApr 2, 2018$2.37M
    Dec 31, 2017-$1.08-$0.46-$0.46 - -$0.46-134.78%MissN/A1N/AFeb 15, 2018$13.00M
    Sep 30, 2017-$0.70-$2.66N/A+73.68%BeatN/AN/AN/ANov 9, 2017$3.30M
    Jun 30, 2017-$0.91-$0.94N/A+3.19%BeatN/AN/AN/AAug 11, 2017$3.76M
    Mar 31, 2017-$0.91-$1.26N/A+27.78%BeatN/AN/AN/AMay 30, 2017$3.84M
    Dec 31, 2016-$1.54-$1.90N/A+18.95%BeatN/AN/AN/AFeb 15, 2017$20.38M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.38, after -$3.01 the year before. It was -$6.23 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.38N/A
    Dec 31, 2024-$3.01N/A
    Dec 31, 2023-$2.28-770.6%
    Dec 31, 2022$0.34N/A
    Dec 31, 2021-$7.74N/A
    Dec 31, 2020-$3.39N/A
    Dec 31, 2019-$2.07N/A
    Dec 31, 2018-$2.57N/A
    Dec 31, 2017-$3.60N/A
    Dec 31, 2016-$6.23N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,57015
    2026Q2Jun 30, 20265,42815
    2026Q1Mar 31, 20265,88916
    2025Q4Dec 31, 20257,13316
    2025Q3Sep 30, 20256,23613
    2025Q2Jun 30, 20255,89015
    2025Q1Mar 31, 20255,66114
    2024Q4Dec 31, 20246,60415

    2026Q3 Earnings Call

    Opening remarks

    Neda Safarzadeh Vice President, Head of Investor Relations, Public Relations and Marketing Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics' quarterly financial update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO, and Dennis Mulroy, our Chief Financial Officer. Dr. Pad Chivukula, our CSO and COO, and Dr. Alan Cohen, our Chief Medical Officer, will join them for the Q&A session. Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by this statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the Risk Factors section in our most recent Form 10-K and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. And with that, I will now turn the call over to Joe.

    Joseph Payne President and CEO Thank you, Neda. Good afternoon, everyone, and thank you for joining us today. The third quarter was an important period for Arcturus as we continued to advance our key clinical programs, introduced our next-generation LUNAR 2.0 delivery platform, and expanded our pipeline of mRNA therapeutics. I'd like to begin with our liver therapeutics franchise, where we believe we are entering a new, exciting phase of development. In September, we presented encouraging Phase II data from ARCT-810 in patients with ornithine transcarbamylase, or OTC, deficiency. At the 0.3 and 0.5 milligram per kilogram dose levels, ARCT-810 demonstrated meaningful biomarker activity, reducing and/or maintaining first morning fasting ammonia within the normal range, including during increased protein intake, and reducing glutamine levels in all participants, with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment. It was generally safe and well tolerated. These results provide important clinical validation of our mRNA approach to liver therapeutics and contributed to the development of our next-generation OTC program, called ARCT-2601. ARCT-2601 is particularly significant for Arcturus because it is the first mRNA therapeutic candidate utilizing our new LUNAR 2.0 delivery technology. Nonhuman primate models have consistently demonstrated strong translational predictivity for lipid nanoparticle-formulated RNA therapeutics. This is well documented. In nonhuman primates, we can measure human ornithine transcarbamylase expression.

    Frequently Asked Questions About ARCT

    When is Arcturus Therapeutics Holdings's next earnings date?

    Arcturus Therapeutics Holdings's next earnings report is expected for Mar 1, 2027.

    Did ARCT beat earnings estimates last quarter?

    Yes. Arcturus Therapeutics Holdings reported EPS of -$0.26 for the quarter ended Sep 30, 2026, above the -$0.60 estimate, a 56.67% surprise.

    What EPS do analysts expect from ARCT next quarter?

    The consensus EPS estimate for Arcturus Therapeutics Holdings for the quarter ending Dec 31, 2026 is -$0.92 from 15 analysts, with estimates from -$1.52 to -$0.55.

    How often does ARCT beat earnings estimates?

    Arcturus Therapeutics Holdings beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +9.47%.